Dyne Therapeutics, Inc. (DYN)
16.74
+1.02
(+6.49%)
USD |
NASDAQ |
Oct 27, 13:10
Dyne Therapeutics Enterprise Value : 1.939B for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 1.939B |
| October 23, 2026 | 1.923B |
| October 22, 2026 | 1.948B |
| October 21, 2026 | 1.997B |
| October 20, 2026 | 2.030B |
| October 19, 2026 | 1.858B |
| October 16, 2026 | 1.696B |
| October 15, 2026 | 1.868B |
| October 14, 2026 | 1.827B |
| October 13, 2026 | 1.870B |
| October 12, 2026 | 1.979B |
| October 09, 2026 | 2.092B |
| October 08, 2026 | 2.047B |
| October 07, 2026 | 1.981B |
| October 06, 2026 | 1.886B |
| October 05, 2026 | 1.893B |
| October 02, 2026 | 1.853B |
| October 01, 2026 | 1.956B |
| September 30, 2026 | 2.004B |
| September 29, 2026 | 2.020B |
| September 28, 2026 | 2.042B |
| September 25, 2026 | 1.991B |
| September 24, 2026 | 2.070B |
| September 23, 2026 | 2.024B |
| September 22, 2026 | 2.174B |
| Date | Value |
|---|---|
| September 21, 2026 | 2.171B |
| September 18, 2026 | 2.170B |
| September 17, 2026 | 2.327B |
| September 16, 2026 | 2.202B |
| September 15, 2026 | 2.300B |
| September 14, 2026 | 2.403B |
| September 11, 2026 | 2.352B |
| September 10, 2026 | 2.387B |
| September 09, 2026 | 2.514B |
| September 08, 2026 | 2.700B |
| September 04, 2026 | 3.357B |
| September 03, 2026 | 3.468B |
| September 02, 2026 | 3.500B |
| September 01, 2026 | 3.493B |
| August 31, 2026 | 3.548B |
| August 28, 2026 | 3.488B |
| August 27, 2026 | 3.657B |
| August 26, 2026 | 3.702B |
| August 25, 2026 | 3.699B |
| August 24, 2026 | 3.641B |
| August 21, 2026 | 3.659B |
| August 20, 2026 | 3.639B |
| August 19, 2026 | 3.772B |
| August 18, 2026 | 3.642B |
| August 17, 2026 | 3.667B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 527.17M |
| Amgen, Inc. | 283.68B |
| Anika Therapeutics, Inc. | 271.49M |
| BioCryst Pharmaceuticals, Inc. | 2.495B |
| Imunon, Inc. | 6.720M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -178.56M |
| Total Expenses (Quarterly) | 178.56M |
| EPS Diluted (Quarterly) | -1.079 |
| Earnings Yield | -19.90% |
| Normalized Earnings Yield | -19.90 |